| Stereochemistry | RACEMIC |
| Molecular Formula | C11H18N4O4 |
| Molecular Weight | 270.285 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC=C(N1CC(O)CN2CCOCC2)[N+]([O-])=O
InChI
InChIKey=GAZGHCHCYRSPIV-UHFFFAOYSA-N
InChI=1S/C11H18N4O4/c1-9-12-6-11(15(17)18)14(9)8-10(16)7-13-2-4-19-5-3-13/h6,10,16H,2-5,7-8H2,1H3
| Molecular Formula | C11H18N4O4 |
| Molecular Weight | 270.285 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Morinidazole is a novel third generation 5-nitroimidazole-class antimicrobial agent indicated for the treatment of anaerobic bacterial infections including appendicitis and pelvic inflammatory disease. Morinidazole is administered as a racemate. Morinidazole was approved by China Food and Drug Administration (CFDA) on February, 2014. The bactericidal activity of morinidazole, depends on the formation of a redox intermediate metabolite in the bacterium that causes DNA strand breakage, inhibits repair, and, ultimately leads to cell death. The main adverse effects (all are mild) relate to the drug are dizziness, drowsiness and nausea. Recent in vitro assays have demonstrated that higher antiparasitic potency is observed in S- morinidazole than in R-morinidazole.
Originator
Approval Year
PubMed
Sample Use Guides
500 mg (100 mL injection) twice daily every 6-8 hours continuously for 5-7 days
Route of Administration:
Intravenous
Minimum inhibitory concentration (MIC) of Morinidazole to several anaerobic bacteria: Peptostreptococcus anaerobius (0.25 mg/l); Veillonella parvula (0.31 mg/l); Actinomyces dentocariosus (0.25 mg/l); Porphyromonas gingivalis (2.0 mg/l); Bacteroides thetaiotaomicron (4.0); Prevotella melaninogenica (0.5 mg/l).
